Free Functional Assessment
AI-powered root cause analysis & care plan
Start Free
Preferred vendor Β· Learn more
The FOXO4-DRI + Epithalon stack is an advanced longevity protocol combining senolytic therapy with telomere preservation. FOXO4-DRI selectively induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction that keeps zombie cells alive. Senescent cells accumulate with age, secreting inflammatory SASP factors that damage surrounding tissue. Epithalon activates telomerase to protect telomere length in healthy cells. The synergy: FOXO4-DRI clears damaged senescent cells while epithalon ensures remaining healthy cells maintain replicative capacity. This is experimental due to limited FOXO4-DRI human data.
FOXO4-DRI is a D-retro-inverso peptide that disrupts the FOXO4-p53 interaction in senescent cells. Normally, FOXO4 sequesters p53 in the nucleus of senescent cells, preventing apoptosis. FOXO4-DRI competitively disrupts this binding, releasing p53 to trigger programmed cell death specifically in senescent cells while leaving healthy cells unaffected.
After clearing senescent cells with FOXO4-DRI, the remaining healthy cell population benefits from epithalon telomerase activation. This preserves their replicative capacity, preventing them from entering senescence prematurely. The sequential approach - clear the damaged, protect the healthy - addresses aging from both the damage accumulation and prevention angles.
| Protocol | Compound 1 | Compound 2 | Timing | Duration |
|---|---|---|---|---|
| Standard | FOXO4-DRI 5mg/kg x 3 days | Epithalon 5mg/day x 10 days | Quarterly + biannual | 3 + 10 days/cycle |
| Conservative | FOXO4-DRI 3mg/kg x 3 days | Epithalon 5mg/day x 10 days | Quarterly + biannual | 3 + 10 days |
| Sequential | FOXO4-DRI 5mg/kg x 3 days, then Epi day 7 | Epithalon 10mg/day x 10 days | Sequential | ~2 weeks combined |
| Panel | Markers | Timing |
|---|---|---|
| SASP Markers | CRP, IL-6, TNF-alpha, MCP-1 | Baseline, 2 weeks post-FOXO4, 3 months |
| Telomere | Telomere length (qPCR) | Baseline, 6 months |
| Basic | CBC, CMP, LFTs, BUN/Cr | Baseline, 1 week post-FOXO4, monthly |
SASP markers (IL-6, TNF-alpha) should decrease after FOXO4-DRI as senescent cell burden reduces. Telomere length tracks epithalon effects over 6-12 months. Liver/kidney function must be monitored.
Quarterly (every 3 months) based on animal research. Each cycle is only 3 days. Conservative cycling with thorough monitoring is essential given limited human data.
No. FOXO4-DRI selectively disrupts FOXO4-p53 binding specific to senescent cells, offering more precise targeting than Q+D. However, it is much less studied in humans and more expensive. Q+D remains more established.
FOXO4-DRI clears senescent cells releasing inflammatory SASP factors. Epithalon then activates telomerase in remaining healthy cells. This clear-and-protect approach addresses aging from both damage removal and preservation angles.
Quarterly (every 3 months) based on animal research. Each cycle is only 3 days. Conservative cycling with thorough monitoring is essential given limited human data.
No. FOXO4-DRI selectively disrupts FOXO4-p53 binding specific to senescent cells, offering more precise targeting than Q+D. However, it is much less studied in humans and more expensive. Q+D remains more established.
FOXO4-DRI clears senescent cells releasing inflammatory SASP factors. Epithalon then activates telomerase in remaining healthy cells. This clear-and-protect approach addresses aging from both damage removal and preservation angles.
Quarterly (every 3 months) based on animal research. Each cycle is only 3 days. Conservative cycling with thorough monitoring is essential given limited human data.
No. FOXO4-DRI selectively disrupts FOXO4-p53 binding specific to senescent cells, offering more precise targeting than Q+D. However, it is much less studied in humans and more expensive. Q+D remains more established.